Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab Phase 2 in RA with Inadequate Response to TNF Inhibitors
NCT00689728Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2008
- Primary completion
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of tabalumab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Jun 2008; status: completed.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00689728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00689728.